CTLA4 and hepatocellular carcinoma: Recently, the FDA approved of the combination of durvalumab, an anti PD-L1 antibody, and tremelimumab, an anti-CTLA-4 antibody, after the HIMALAYA Study showed an improvement in overall survival for patients with non-resectable HCC (33).